Pargyline | CAS# 555-57-7

MedKoo Cat#: 571043 | Name: Pargyline

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pargyline is an irreversible selective monoamine oxidase (MAO)-B inhibitor drug with antihypertensive properties. Pargyline has been found to bind with high affinity to the I2 imidazoline receptor (an allosteric site on the MAO enzyme).

Chemical Structure

Pargyline

CAS#555-57-7

Theoretical Analysis

MedKoo Cat#: 571043

Name: Pargyline

CAS#: 555-57-7

Chemical Formula: C11H13N

Exact Mass: 159.1048

Molecular Weight: 159.23

Elemental Analysis: C, 82.97; H, 8.23; N, 8.80

Price and Availability

Size	Price	Availability	Quantity
1g	USD 370.00
5g	USD 890.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Pargyline; Eudatin

IUPAC/Chemical Name

Benzenemethanamine, N-methyl-N-2-propynyl-

InChi Key

DPWPWRLQFGFJFI-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3

SMILES Code

C#CCN(C)CC1=CC=CC=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B.

In vitro activity:

The purpose of this study was to investigate the effects of the MAO inhibitors, pargyline and tranylcypromine on cell survival in human prostate carcinoma (LNCaP-LN3) cells. The proliferation of cells exposed to pargyline decreased in a dose- and time-dependent manner, while tranylcypromine-treated cells showed the opposite results. Treatment with pargyline significantly induced cell cycle arrest at the G1 phase compared to the control and tranylcypromine-treated cells. In addition, pargyline induced an increase in the cell death rate by promoting apoptosis; however, tranylcypromine had no effect on LNCaP-LN3 cells. Reference: Oncol Rep. 2013 Oct;30(4):1587-92. https://pubmed.ncbi.nlm.nih.gov/23900512/

In vivo activity:

SCID mice were injected subcutaneously with LNCap cells. Pargyline was given intraperitoneally or not after castration (implemented with Bilateral orchidectomy), then PSA levels in serum and tumor were determined to assess time to androgen-independent progression. The results showed that LSD1 expression was up-regulated when PCa progressed to Castration Resistant Prostate Cancer (CRPC). Pargyline reduced LNCap cells migration and invasion ability, and inhibited the process of EMT by up-regulating expression of E-cadherin, and down-regulating expressions of N-cadherin and Vimentin in vitro and in vivo. Although, Pargyline did not change the level of AR, it reduced PSA expression both in vitro and in vivo. Furthermore, Pargyline delayed prostate cancer transition from androgen-dependent to androgen-independent state (CRPC). Reference: Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. https://pubmed.ncbi.nlm.nih.gov/26435505/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	628.01

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 159.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92. doi: 10.3892/or.2013.2635. Epub 2013 Jul 24. PMID: 23900512; PMCID: PMC3810355. 2. Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. doi: 10.1016/j.bbrc.2015.09.164. Epub 2015 Oct 3. PMID: 26435505. 3. Chaaya R, Alfarano C, Guilbeau-Frugier C, Coatrieux C, Kesteman AS, Parini A, Fares N, Gue M, Schanstra JP, Bascands JL. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol Dial Transplant. 2011 Feb;26(2):489-98. doi: 10.1093/ndt/gfq445. Epub 2010 Jul 28. PMID: 20667995.

In vitro protocol:

In vivo protocol:

1. Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. doi: 10.1016/j.bbrc.2015.09.164. Epub 2015 Oct 3. PMID: 26435505. 2. Chaaya R, Alfarano C, Guilbeau-Frugier C, Coatrieux C, Kesteman AS, Parini A, Fares N, Gue M, Schanstra JP, Bascands JL. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol Dial Transplant. 2011 Feb;26(2):489-98. doi: 10.1093/ndt/gfq445. Epub 2010 Jul 28. PMID: 20667995.

1: Bazzu G, Rocchitta G, Migheli R, Alvau MD, Zinellu M, Puggioni G, Calia G, Mercanti G, Giusti P, Desole MS, Serra PA. Effects of the neurotoxin MPTP and pargyline protection on extracellular energy metabolites and dopamine levels in the striatum of freely moving rats. Brain Res. 2013 Nov 13;1538:159-71. doi: 10.1016/j.brainres.2013.09.037. Epub 2013 Sep 27. PubMed PMID: 24080403. 2: Lei J, Wu X, Zhu Q. Copper-catalyzed trifluoromethylalkynylation of isocyanides. Org Lett. 2015 May 15;17(10):2322-5. doi: 10.1021/acs.orglett.5b00730. Epub 2015 Apr 23. PubMed PMID: 25905786. 3: Wang J, Edmondson DE. Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Biochemistry. 2011 Apr 5;50(13):2499-505. doi: 10.1021/bi101722b. Epub 2011 Mar 7. PubMed PMID: 21341713; PubMed Central PMCID: PMC3068223. 4: Rao BV, Manmode S, Hotha S. Propargyl 1,2-orthoesters for a catalytic and stereoselective synthesis of pyrimidine nucleosides. J Org Chem. 2015 Feb 6;80(3):1499-505. doi: 10.1021/jo502413z. Epub 2015 Jan 8. PubMed PMID: 25539179.